By Tarun Sai Lomte Reviewed by Susha Cheriyedath, M.Sc. Sep 15 2025 New genetic evidence suggests that targeting GIPR and GLP1R could reduce harmful drinking patterns while improving liver and metabolic health, opening the door to repurposing existing metabolic drugs for alcohol use disorders. Study: Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study . Image Credit: Voyagerix /